Supplemental Digital Content, containing 6 tables. The Supplemental Digital Content was not copyedited by *Archives of Pathology & Laboratory Medicine*.

Table S1. Clinicopathologic findings assessed by tumor length (<1 mm) and GG on biopsy.

<1 mm	GG1 (N=90)	GG2-4 (N=24)	P	GG1-2 (N=106)	GG3-4 (N=8)	P
Age (mean, year)	62.0	64.1	.11	61.8	66.4	.15
PSA (mean, ng/mL)	6.58	6.92	.15	6.48	8.89	.25
Prostatectomy GG2-5	47.8%	100%	<.001	55.7%	100%	.02
Prostatectomy GG3-5	2.2%	29.2%	<.001	3.8%	62.5%	<.001
Prostatectomy GG4-5	0%	4.2%	.21	0%	12.5%	.07
pT3	4.4%	4.2%	>.99	4.7%	0%	>.99
pT3b	0%	4.3%	>.99	0%	0%	>.99
pN1	0%	0%	>.99	0%	0%	>.99
Positive surgical margin	3.3%	0%	.60	2.8%	0%	>.99
Tumor volume (mean, cc)	2.96	4.21	<.001	3.15	4.16	.41

PSA, prostate-specific antigen; GG, Grade Group

Table S2. Clinicopathologic findings assessed by tumor length (<2 mm) and GG on biopsy.

<2 mm	GG1 (N=90)	GG2-4 (N=24)	P	GG1-2 (N=106)	GG3-4 (N=8)	P
Age (mean, year)	62.0	64.1	.11	61.8	66.4	.15
PSA (mean, ng/mL)	6.58	6.92	.15	6.48	8.89	.25
Prostatectomy GG2-5	47.8%	100%	<.001	55.7%	100%	.02
Prostatectomy GG3-5	2.2%	29.2%	<.001	3.8%	62.5%	<.001
Prostatectomy GG4-5	0%	4.2%	.21	0%	12.5%	.07
pT3	4.4%	4.2%	>.99	4.7%	0%	>.99
pT3b	0%	4.3%	>.99	0%	0%	>.99
pN1	0%	0%	>.99	0%	0%	>.99
Positive surgical margin	3.3%	0%	.60	2.8%	0%	>.99
Tumor volume (mean, cc)	2.96	4.21	<.001	3.15	4.16	.41

PSA, prostate-specific antigen; GG, Grade Group

Table S3. Clinicopathologic findings assessed by tumor length (≥1/<2 mm) and GG on biopsy.

≥1/<2 mm	GG1 (N=62)	GG2-4 (N=20)	P	GG1-2 (N=77)	GG3-4 (N=5)	P
Age (mean, year)	62.7	63.9	.57	62.6	70.4	.03
PSA (mean, ng/mL)	6.34	9.56	.047	7.09	7.60	.86
Prostatectomy GG2-5	43.5%	95.0%	<.001	53.2%	100%	.06
Prostatectomy GG3-5	4.8%	30.0%	.006	7.8%	60.0%	.008
Prostatectomy GG4-5	0%	5.0%	.24	0%	20.0%	.06
pT3	12.9%	30.0%	.09	13.7%	40.0%	.20
pT3b	0%	0%	>.99	0%	0%	>.99
pN1	0%	0%	>.99	0%	0%	>.99
Positive surgical margin	6.5%	5.0%	>.99	6.5%	0%	>.99
Tumor volume (mean, cc)	2.91	4.68	.01	3.28	6.06	.03

PSA, prostate-specific antigen; GG, Grade Group

Table S4. Clinicopathologic findings assessed by tumor length (≥2/<3 mm) and GG on biopsy.

≥2/<3 mm	GG1 (N=22)	GG2-4 (N=13)	P	GG1-2 (N=27)	GG3-4 (N=8)	P
Age (mean, year)	61.0	65.1	.14	60.3	69.9	<.001
PSA (mean, ng/mL)	5.75	8.71	.02	6.36	8.51	.16
Prostatectomy GG2-5	50.0%	92.3%	.02	55.6%	100%	.03
Prostatectomy GG3-5	4.5%	38.5%	.02	3.7%	62.5%	<.001
Prostatectomy GG4-5	0%	7.7%	.37	0%	12.5%	.23
pT3	9.1%	23.1%	.34	11.1%	25.0%	.57
pT3b	0%	7.7%	.37	0%	12.5%	.23
pN1	0%	0%	>.99	0%	0%	>.99
Positive surgical margin	4.5%	0%	>.99	3.7%	0%	>.99
Tumor volume (mean, cc)	3.39	5.41	.11	3.28	7.04	.007

PSA, prostate-specific antigen; GG, Grade Group

Table S5. Clinicopathologic findings assessed by tumor length (<3 mm) and GG on biopsy.

<3 mm	GG1 (N=174)	GG2-4 (N=57)	P	GG1-2 (N=210)	GG3-4 (N=21)	P
Age (mean, year)	61.9	64.2	.04	61.9	68.4	<.001
PSA (mean, ng/mL)	6.39	8.26	.01	6.69	8.44	.26
Prostatectomy GG2-5	46.6%	96.5%	<.001	54.8%	100%	<.001
Prostatectomy GG3-5	3.4%	31.6%	<.001	5.2%	61.9%	<.001
Prostatectomy GG4-5	0%	5.3%	.01	0%	14.3%	<.001
pT3	8.0%	17.5%	.04	9.5%	19.0%	.25
pT3b	0%	1.8%	.25	0%	4.8%	.09
pN1	0%	0%	>.99	0%	0%	>.99
Positive surgical margin	4.6%	1.8%	.46	4.3%	0%	.61
Tumor volume (mean, cc)	2.99	4.65	<.001	3.21	5.27	.006

PSA, prostate-specific antigen; GG, Grade Group

Table S6. Clinicopathologic findings assessed by tumor length (≥3 mm) and GG on biopsy.

≥3 mm	GG1 (N=28)	GG2-4 (N=36)	P	GG1-2 (N=50)	GG3-4 (N=14)	P
Age (mean, year)	63.5	63.9	.82	63.9	62.9	.61
PSA (mean, ng/mL)	5.80	7.14	.20	6.32	7.48	.37
Prostatectomy GG2-5	71.4%	100%	<.001	84.0%	100%	.18
Prostatectomy GG3-5	3.6%	36.1%	.002	8.0%	71.4%	<.001
Prostatectomy GG4-5	3.6%	2.8%	>.99	2.0%	7.1%	.39
pT3	21.4%	36.1%	.20	26.0%	42.9%	.32
pT3b	0%	8.3%	.25	0%	21.4%	.009
pN1	0%	5.6%	>.99	2.0%	7.1%	>.99
Positive surgical margin	17.9%	11.1%	.49	12.0%	21.4%	.40
Tumor volume (mean, cc)	4.27	5.83	.14	4.77	6.50	.17

PSA, prostate-specific antigen; GG, Grade Group